Zacks Investment Research
21 Nov 2025, 14:06 UTC · 43w ago
Verdict
Headline takes no side. We score COLL +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Collegium Pharmaceutical's board authorized a $150 million share repurchase program through the end of 2026.
So whatSignificant buybacks reduce share float and signal management confidence in the company's valuation.
More positive than 92% of claims this week
Collegium has expanded its ADHD commercial operations for Jornay PM by deploying approximately 180 trained sales representatives.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 77% of claims this week
Collegium Pharmaceutical is currently designated as a Zacks Rank #1 (Strong Buy).
More positive than 65% of claims this week
Collegium executed a $25 million accelerated share repurchase (ASR) deal with Jefferies in May.
More positive than 54% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
Described as having a 'Strong Buy' Zacks Rank, implementing aggressive share buybacks, and expanding its ADHD commercial operations.
More positive than 87% of ticker scores this week
Carries a Zacks Rank #1 (Strong Buy) and has seen significant year-to-date share price appreciation.
More positive than 64% of ticker scores this week
While it has a lower Zacks Rank (#3 Hold) than its peers, the stock has advanced 45.5% year to date.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
2d ago
More positive than 78% of relationship scores this week
[mutual] Collegium competes with ANI Pharmaceuticals in the neuropsychiatry space.
More positive than 35% of relationship scores this week
[mutual] Both companies are identified as competitors to Collegium within the same pharmaceutical niche.
−48.2%
Price is moving against the score
$22.77 vs $43.95 close before publication (Nov 20) · not market-adjusted
COLL chart →
